Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Multiple Cancer Types

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Lung, Non Small Cell
II
Iams, Wade
NCT03539536
VICCTHO18125

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: